Methods and compositions for inhibition of angiogenesis
US7435745B2 · kind B2 · utility
55Cited by
24References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 26, 2006 |
| Grant date | Oct 14, 2008 |
| Priority date | — |
| Expiry date | Apr 26, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.